Cipla and Pfizer Forge Landmark Deal to Expand Medicine Access in India

Cipla Ltd and Pfizer India have entered an exclusive agreement granting Cipla rights to market, distribute, and sell four Pfizer brands in India. This partnership aims to combine Pfizer's established products with Cipla's extensive distribution network, improving medicine availability across the country.

Cipla Ltd has signed an exclusive agreement with Pfizer India to market, distribute, and sell Pfizer's four key pharmaceutical brands across India.

Under this partnership, Cipla gains the exclusive rights to market and distribute the cough syrup Corex Dx and Corex LS, anti-inflammatory drug Dolonex, proton pump inhibitor Neksium, and antibiotic Dalacin C in India. Pfizer will continue to manufacture and supply these products.

As the first collaboration of this kind between Pfizer and Cipla in India, the initiative aims to leverage Pfizer's product portfolio and Cipla's distribution strengths to reach more patients across the nation, a joint statement from the companies confirmed. Both executives from Pfizer and Cipla emphasized the partnership's goal of enhancing access to high-quality medicines in India.

(With inputs from agencies.)